Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data

Keyphrases

• Diabetes 100%
• Serum Uric Acid 100%
• Egfr 100%
• Double-blind Trial 100%
• Baseline Data 100%
• Diabetic Kidney Disease 100%
• Allopurinol 100%
• Design Information 100%
• Renal Loss 100%
• Type I Diabetes 60%
• Type 1 Diabetes Mellitus (T1DM) 60%
• Albuminuria 60%
• Glomerular Filtration Rate 60%
• Normoalbuminuria 60%
• Moderate to Severe 40%
• Hemoglobin A1c (HbA1c) 40%
• Kidney Function 40%
• Loss Rate 40%
• Iohexol 40%
• Hypertension 20%
• Placebo 20%
• Placebo-controlled 20%
• Multicenter Trial 20%
• Diabetes Duration 20%
• Blood Pressure 20%
• Estimated Glomerular Filtration Rate 20%
• Washout Period 20%
• Renin-angiotensin System Inhibitors 20%
• Comparing Groups 20%
• Baseline Characteristics 20%
• Design Characteristics 20%
• Disease Risk Factors 20%
• EGFR Decline 20%
• EGFR Slope 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Uric Acid 100%
• Diabetic Nephropathy 100%
• Allopurinol 100%
• Insulin Dependent Diabetes Mellitus 60%
• Albuminuria 60%
• Placebo 40%
• Iohexol 40%
• Renin-Angiotensin System Inhibitor 20%